Anny Wong has a diverse background in science and healthcare.
Trained as a molecular pharmacologist and biomedical scientist, she provides in-depth technical knowledge in pharmacological therapeutic treatment in cancer and other diseases to support clients navigating the regulatory strategy and FDA policy environment.
Prior to joining Avalere, Anny was a partner at a start-up company, CellGro Technologies, LLC, where she managed the strategic business and scientific operations for developing novel cell-culturing instruments and devices for CAR-T cell manufacturing. Additionally, she was a consultant at Stanford Healthcare Consulting Group advising healthcare providers on improving and streamlining healthcare management, operations, performances, and quality improvements. She did her post-PhD training at Stanford University developing clinical early detection biomarkers for kidney damage, researching genetic factors involvement in cancer progression, and pursuing many other projects. Prior to that, she worked as a research analyst for HHS, where she designed and conducted statistical research to develop and evaluate healthcare delivery systems, financing, public health policies, and epidemiology.
Anny obtained her PhD in pharmacology and BS in chemistry from Creighton University.